相似文献
1
Bronchopulmonary disposition of micafungin in healthy adult volunteers.
Antimicrob Agents Chemother. 2009 Mar;53(3):1218-20. doi: 10.1128/AAC.01386-08. Epub 2008 Dec 29.
2
Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients.
Antimicrob Agents Chemother. 2010 Aug;54(8):3451-9. doi: 10.1128/AAC.01647-09. Epub 2010 May 3.
3
Micafungin concentrations in the plasma and burn eschar of severely burned patients.
Antimicrob Agents Chemother. 2012 Feb;56(2):1113-5. doi: 10.1128/AAC.05381-11. Epub 2011 Nov 14.
4
Population pharmacokinetics of micafungin in neonates and young infants.
Antimicrob Agents Chemother. 2010 Jun;54(6):2633-7. doi: 10.1128/AAC.01679-09. Epub 2010 Mar 22.
5
Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01398-17. Print 2017 Dec.
6
Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
Biol Blood Marrow Transplant. 2010 Oct;16(10):1458-62. doi: 10.1016/j.bbmt.2010.05.002. Epub 2010 Jun 20.
7
Micafungin Plasma Levels Are Not Affected by Continuous Renal Replacement Therapy: Experience in Critically Ill Patients.
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.02425-16. Print 2017 Aug.
8
Prediction of micafungin area under the curve data by using peak concentration: applicability and utility in antifungal therapy.
Future Microbiol. 2016;11(4):485-90. doi: 10.2217/fmb.16.3. Epub 2016 Apr 12.
9
Maintenance of therapeutic concentrations of micafungin administered 5 days/week in a leukemic adolescent with invasive candidiasis.
Clin Microbiol Infect. 2014 Nov;20(11):O975-6. doi: 10.1111/1469-0691.12620. Epub 2014 Apr 5.
10
Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection.
Antimicrob Agents Chemother. 2016 Sep 23;60(10):5914-21. doi: 10.1128/AAC.00727-16. Print 2016 Oct.
引用本文的文献
1
Human Tissue Distribution of Anidulafungin and Micafungin.
Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0016921. doi: 10.1128/AAC.00169-21.
2
Mutant Prevention Concentration and Mutant Selection Window of Micafungin and Anidulafungin in Clinical Candida glabrata Isolates.
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.01982-17. Print 2018 Mar.
3
Clinical Pharmacokinetics and Pharmacodynamics of Micafungin.
Clin Pharmacokinet. 2018 Mar;57(3):267-286. doi: 10.1007/s40262-017-0578-5.
4
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.
Infection. 2017 Dec;45(6):737-779. doi: 10.1007/s15010-017-1042-z. Epub 2017 Jul 12.
5
Tissue penetration of antifungal agents.
Clin Microbiol Rev. 2014 Jan;27(1):68-88. doi: 10.1128/CMR.00046-13.
6
Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections.
Drugs. 2012 Nov 12;72(16):2141-65. doi: 10.2165/11209970-000000000-00000.
7
Micafungin for Candida albicans pacemaker-associated endocarditis: a case report and review of the literature.
Mycopathologia. 2013 Feb;175(1-2):129-34. doi: 10.1007/s11046-012-9591-2. Epub 2012 Oct 17.
8
Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents.
Clin Pharmacokinet. 2011 Nov 1;50(11):689-704. doi: 10.2165/11592900-000000000-00000.
9
Echinocandin antifungal drugs in fungal infections: a comparison.
Drugs. 2011 Jan 1;71(1):11-41. doi: 10.2165/11585270-000000000-00000.
10
Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients.
Antimicrob Agents Chemother. 2010 Aug;54(8):3451-9. doi: 10.1128/AAC.01647-09. Epub 2010 May 3.
本文引用的文献
1
Role of plasma proteins in pharmacokinetics of micafungin, an antifungal antibiotic, in analbuminemic rats.
Antimicrob Agents Chemother. 2008 Sep;52(9):3454-6. doi: 10.1128/AAC.00396-08. Epub 2008 Jun 30.
2
Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis.
J Antimicrob Chemother. 2008 May;61(5):1140-4. doi: 10.1093/jac/dkn069. Epub 2008 Feb 27.
3
Characterisation of the phagocytic uptake of Aspergillus fumigatus conidia by macrophages.
Microbes Infect. 2008 Feb;10(2):175-84. doi: 10.1016/j.micinf.2007.11.001. Epub 2007 Nov 17.
4
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.
Clin Infect Dis. 2008 Feb 1;46(3):327-60. doi: 10.1086/525258.
5
Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia.
Antimicrob Agents Chemother. 2008 Jan;52(1):321-8. doi: 10.1128/AAC.00699-07. Epub 2007 Oct 15.
6
Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
Antimicrob Agents Chemother. 2008 Jan;52(1):92-7. doi: 10.1128/AAC.00875-07. Epub 2007 Oct 8.
7
Aspergillus fumigatus: principles of pathogenesis and host defense.
Eukaryot Cell. 2007 Nov;6(11):1953-63. doi: 10.1128/EC.00274-07. Epub 2007 Sep 21.
8
Effects of serum on in vitro susceptibility testing of echinocandins.
Antimicrob Agents Chemother. 2007 Nov;51(11):4214-6. doi: 10.1128/AAC.01589-06. Epub 2007 Sep 4.
9
Serum differentially alters the antifungal properties of echinocandin drugs.
Antimicrob Agents Chemother. 2007 Jun;51(6):2253-6. doi: 10.1128/AAC.01536-06. Epub 2007 Apr 9.
10
Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy.
J Infect Dis. 2007 Feb 1;195(3):455-66. doi: 10.1086/510535. Epub 2006 Dec 21.
Zotero 插件